questionsmedicales.fr
Composés hétérocycliques
Composés hétérocycliques à cycles fusionnés
Composés hétérobicycliques
Isoquinoléines
Tétrahydroisoquinoléines
Tétrahydroisoquinoléines : Questions médicales fréquentes
Termes MeSH sélectionnés :
Neovascularization, Pathologic
Diagnostic
5
Intoxication
Tétrahydroisoquinoléines
Analyse sanguine
Tétrahydroisoquinoléines
Symptômes
Tétrahydroisoquinoléines
Marqueurs biologiques
Tétrahydroisoquinoléines
Exposition chronique
Tétrahydroisoquinoléines
Symptômes
5
Surdose
Tétrahydroisoquinoléines
Effets neurologiques
Tétrahydroisoquinoléines
Réactions allergiques
Tétrahydroisoquinoléines
Système cardiovasculaire
Tétrahydroisoquinoléines
Troubles psychologiques
Tétrahydroisoquinoléines
Prévention
5
Travailleurs
Tétrahydroisoquinoléines
Sensibilisation
Tétrahydroisoquinoléines
Sécurité en laboratoire
Tétrahydroisoquinoléines
Traitements
5
Antidotes
Tétrahydroisoquinoléines
Effets secondaires
Tétrahydroisoquinoléines
Hospitalisation
Tétrahydroisoquinoléines
Interactions médicamenteuses
Tétrahydroisoquinoléines
Complications
5
Complications
Tétrahydroisoquinoléines
Dommages permanents
Tétrahydroisoquinoléines
Dépendance
Tétrahydroisoquinoléines
Santé mentale
Tétrahydroisoquinoléines
Interactions médicamenteuses
Tétrahydroisoquinoléines
Facteurs de risque
5
Facteurs de risque
Intoxication
Antécédents médicaux
Tétrahydroisoquinoléines
Personnes âgées
Tétrahydroisoquinoléines
Interactions médicamenteuses
Tétrahydroisoquinoléines
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Tétrahydroisoquinoléines : Questions médicales les plus fréquentes",
"headline": "Tétrahydroisoquinoléines : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Tétrahydroisoquinoléines : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-06-20",
"dateModified": "2026-03-12",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Tétrahydroisoquinoléines"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Isoquinoléines",
"url": "https://questionsmedicales.fr/mesh/D007546",
"about": {
"@type": "MedicalCondition",
"name": "Isoquinoléines",
"code": {
"@type": "MedicalCode",
"code": "D007546",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D03.633.100.531"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Quinapril",
"alternateName": "Quinapril",
"url": "https://questionsmedicales.fr/mesh/D000077583",
"about": {
"@type": "MedicalCondition",
"name": "Quinapril",
"code": {
"@type": "MedicalCode",
"code": "D000077583",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D03.633.100.531.820.250"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Salsolines",
"alternateName": "Salsoline Alkaloids",
"url": "https://questionsmedicales.fr/mesh/D012490",
"about": {
"@type": "MedicalCondition",
"name": "Salsolines",
"code": {
"@type": "MedicalCode",
"code": "D012490",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D03.633.100.531.820.500"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Succinate de solifénacine",
"alternateName": "Solifenacin Succinate",
"url": "https://questionsmedicales.fr/mesh/D000069464",
"about": {
"@type": "MedicalCondition",
"name": "Succinate de solifénacine",
"code": {
"@type": "MedicalCode",
"code": "D000069464",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D03.633.100.531.820.594"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Toxiférine",
"alternateName": "Toxiferine",
"url": "https://questionsmedicales.fr/mesh/D014117",
"about": {
"@type": "MedicalCondition",
"name": "Toxiférine",
"code": {
"@type": "MedicalCode",
"code": "D014117",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D03.633.100.531.820.687"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Alcuronium",
"alternateName": "Alcuronium",
"url": "https://questionsmedicales.fr/mesh/D000443",
"about": {
"@type": "MedicalCondition",
"name": "Alcuronium",
"code": {
"@type": "MedicalCode",
"code": "D000443",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D03.633.100.531.820.687.050"
}
}
}
]
},
{
"@type": "MedicalWebPage",
"name": "Trabectédine",
"alternateName": "Trabectedin",
"url": "https://questionsmedicales.fr/mesh/D000077606",
"about": {
"@type": "MedicalCondition",
"name": "Trabectédine",
"code": {
"@type": "MedicalCode",
"code": "D000077606",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D03.633.100.531.820.781"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Tubocurarine",
"alternateName": "Tubocurarine",
"url": "https://questionsmedicales.fr/mesh/D014403",
"about": {
"@type": "MedicalCondition",
"name": "Tubocurarine",
"code": {
"@type": "MedicalCode",
"code": "D014403",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D03.633.100.531.820.875"
}
}
}
],
"about": {
"@type": "MedicalCondition",
"name": "Tétrahydroisoquinoléines",
"alternateName": "Tetrahydroisoquinolines",
"code": {
"@type": "MedicalCode",
"code": "D044005",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Rebecca Roddan",
"url": "https://questionsmedicales.fr/author/Rebecca%20Roddan",
"affiliation": {
"@type": "Organization",
"name": "Department of Chemistry University College London 20 Gordon Street London WC1H 0AJ UK."
}
},
{
"@type": "Person",
"name": "Helen C Hailes",
"url": "https://questionsmedicales.fr/author/Helen%20C%20Hailes",
"affiliation": {
"@type": "Organization",
"name": "Department of Chemistry University College London 20 Gordon Street London WC1H 0AJ UK."
}
},
{
"@type": "Person",
"name": "John M Ward",
"url": "https://questionsmedicales.fr/author/John%20M%20Ward",
"affiliation": {
"@type": "Organization",
"name": "Department of Biochemical Engineering University College London Gower Street, Bernard Katz Building London WC1E 6BT UK."
}
},
{
"@type": "Person",
"name": "Max Cárdenas-Fernández",
"url": "https://questionsmedicales.fr/author/Max%20C%C3%A1rdenas-Fern%C3%A1ndez",
"affiliation": {
"@type": "Organization",
"name": "Department of Biochemical Engineering University College London Gower Street, Bernard Katz Building London WC1E 6BT UK."
}
},
{
"@type": "Person",
"name": "Daniel Méndez-Sánchez",
"url": "https://questionsmedicales.fr/author/Daniel%20M%C3%A9ndez-S%C3%A1nchez",
"affiliation": {
"@type": "Organization",
"name": "Department of Chemistry, Christopher Ingold Building, University College London, London, WC1H 0AJ, UK."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Downregulation of PIK3IP1 in retinal microglia promotes retinal pathological neovascularization via PI3K-AKT pathway activation.",
"datePublished": "2023-08-07",
"url": "https://questionsmedicales.fr/article/37550343",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1038/s41598-023-39473-z"
}
},
{
"@type": "ScholarlyArticle",
"name": "Hyperreflective material in patients with non-neovascular pachychoroid disease.",
"datePublished": "2023-06-06",
"url": "https://questionsmedicales.fr/article/37280611",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1186/s12886-023-03011-2"
}
},
{
"@type": "ScholarlyArticle",
"name": "Preliminary research on LncRNA ATP2B2-IT2 in neovascularization of diabetic retinopathy.",
"datePublished": "2024-06-21",
"url": "https://questionsmedicales.fr/article/38907191",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1186/s12886-024-03523-5"
}
},
{
"@type": "ScholarlyArticle",
"name": "Incidence and Risk Factors of Second Eye Involvement in Myopic Macular Neovascularization.",
"datePublished": "2023-07-08",
"url": "https://questionsmedicales.fr/article/37429427",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.oret.2023.06.025"
}
},
{
"@type": "ScholarlyArticle",
"name": "Research progress of VEGFR small molecule inhibitors in ocular neovascular diseases.",
"datePublished": "2023-05-29",
"url": "https://questionsmedicales.fr/article/37285684",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.ejmech.2023.115535"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Composés hétérocycliques",
"item": "https://questionsmedicales.fr/mesh/D006571"
},
{
"@type": "ListItem",
"position": 3,
"name": "Composés hétérocycliques à cycles fusionnés",
"item": "https://questionsmedicales.fr/mesh/D000072471"
},
{
"@type": "ListItem",
"position": 4,
"name": "Composés hétérobicycliques",
"item": "https://questionsmedicales.fr/mesh/D006574"
},
{
"@type": "ListItem",
"position": 5,
"name": "Isoquinoléines",
"item": "https://questionsmedicales.fr/mesh/D007546"
},
{
"@type": "ListItem",
"position": 6,
"name": "Tétrahydroisoquinoléines",
"item": "https://questionsmedicales.fr/mesh/D044005"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Tétrahydroisoquinoléines - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Tétrahydroisoquinoléines",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2026-05-15",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Tétrahydroisoquinoléines",
"description": "Comment diagnostiquer une intoxication aux tétrahydroisoquinoléines ?\nQuels tests sont utilisés pour détecter les tétrahydroisoquinoléines ?\nQuels symptômes indiquent une exposition aux tétrahydroisoquinoléines ?\nY a-t-il des marqueurs biologiques pour les tétrahydroisoquinoléines ?\nComment évaluer l'exposition chronique aux tétrahydroisoquinoléines ?",
"url": "https://questionsmedicales.fr/mesh/D044005?mesh_terms=Neovascularization,+Pathologic#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Tétrahydroisoquinoléines",
"description": "Quels sont les symptômes d'une surdose de tétrahydroisoquinoléines ?\nLes tétrahydroisoquinoléines causent-elles des effets neurologiques ?\nPeut-on avoir des réactions allergiques aux tétrahydroisoquinoléines ?\nLes tétrahydroisoquinoléines affectent-elles le système cardiovasculaire ?\nQuels troubles psychologiques peuvent être liés aux tétrahydroisoquinoléines ?",
"url": "https://questionsmedicales.fr/mesh/D044005?mesh_terms=Neovascularization,+Pathologic#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Tétrahydroisoquinoléines",
"description": "Comment prévenir l'intoxication aux tétrahydroisoquinoléines ?\nY a-t-il des recommandations pour les travailleurs exposés ?\nLes enfants sont-ils plus à risque d'intoxication ?\nComment sensibiliser le public aux dangers des tétrahydroisoquinoléines ?\nQuelles mesures de sécurité doivent être prises en laboratoire ?",
"url": "https://questionsmedicales.fr/mesh/D044005?mesh_terms=Neovascularization,+Pathologic#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Tétrahydroisoquinoléines",
"description": "Quel traitement est recommandé en cas d'intoxication aux tétrahydroisoquinoléines ?\nY a-t-il des antidotes pour les tétrahydroisoquinoléines ?\nComment gérer les effets secondaires des tétrahydroisoquinoléines ?\nLes tétrahydroisoquinoléines nécessitent-elles une hospitalisation ?\nQuels médicaments peuvent interagir avec les tétrahydroisoquinoléines ?",
"url": "https://questionsmedicales.fr/mesh/D044005?mesh_terms=Neovascularization,+Pathologic#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Tétrahydroisoquinoléines",
"description": "Quelles complications peuvent survenir après une intoxication ?\nLes tétrahydroisoquinoléines peuvent-elles causer des dommages permanents ?\nY a-t-il des risques de dépendance aux tétrahydroisoquinoléines ?\nComment les tétrahydroisoquinoléines affectent-elles la santé mentale ?\nLes tétrahydroisoquinoléines peuvent-elles interagir avec d'autres médicaments ?",
"url": "https://questionsmedicales.fr/mesh/D044005?mesh_terms=Neovascularization,+Pathologic#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Tétrahydroisoquinoléines",
"description": "Quels sont les facteurs de risque d'intoxication aux tétrahydroisoquinoléines ?\nLes antécédents médicaux influencent-ils le risque ?\nLes personnes âgées sont-elles plus à risque ?\nLe mode de vie influence-t-il le risque d'intoxication ?\nLes interactions médicamenteuses augmentent-elles le risque ?",
"url": "https://questionsmedicales.fr/mesh/D044005?mesh_terms=Neovascularization,+Pathologic#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une intoxication aux tétrahydroisoquinoléines ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic repose sur l'historique clinique et des tests toxicologiques spécifiques."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour détecter les tétrahydroisoquinoléines ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des analyses sanguines et urinaires peuvent être effectuées pour détecter ces composés."
}
},
{
"@type": "Question",
"name": "Quels symptômes indiquent une exposition aux tétrahydroisoquinoléines ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent des troubles neurologiques, des nausées et des vertiges."
}
},
{
"@type": "Question",
"name": "Y a-t-il des marqueurs biologiques pour les tétrahydroisoquinoléines ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Actuellement, il n'existe pas de marqueurs biologiques spécifiques pour ces composés."
}
},
{
"@type": "Question",
"name": "Comment évaluer l'exposition chronique aux tétrahydroisoquinoléines ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'évaluation se fait par l'historique d'exposition et des tests de laboratoire réguliers."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes d'une surdose de tétrahydroisoquinoléines ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent agitation, hallucinations, et troubles respiratoires."
}
},
{
"@type": "Question",
"name": "Les tétrahydroisoquinoléines causent-elles des effets neurologiques ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elles peuvent provoquer des effets tels que des convulsions et des troubles de la mémoire."
}
},
{
"@type": "Question",
"name": "Peut-on avoir des réactions allergiques aux tétrahydroisoquinoléines ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des réactions allergiques sont possibles, bien que rares, et peuvent inclure des éruptions cutanées."
}
},
{
"@type": "Question",
"name": "Les tétrahydroisoquinoléines affectent-elles le système cardiovasculaire ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles peuvent provoquer des palpitations et des variations de la pression artérielle."
}
},
{
"@type": "Question",
"name": "Quels troubles psychologiques peuvent être liés aux tétrahydroisoquinoléines ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des troubles tels que l'anxiété et la dépression peuvent être exacerbés par leur consommation."
}
},
{
"@type": "Question",
"name": "Comment prévenir l'intoxication aux tétrahydroisoquinoléines ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Éviter l'exposition à des sources connues et suivre des protocoles de sécurité appropriés."
}
},
{
"@type": "Question",
"name": "Y a-t-il des recommandations pour les travailleurs exposés ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des équipements de protection individuelle et des formations sont recommandés."
}
},
{
"@type": "Question",
"name": "Les enfants sont-ils plus à risque d'intoxication ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les enfants sont plus vulnérables en raison de leur taille et de leur métabolisme."
}
},
{
"@type": "Question",
"name": "Comment sensibiliser le public aux dangers des tétrahydroisoquinoléines ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des campagnes d'information et des formations peuvent aider à sensibiliser le public."
}
},
{
"@type": "Question",
"name": "Quelles mesures de sécurité doivent être prises en laboratoire ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Utiliser des hottes, des gants et des lunettes de protection lors de la manipulation."
}
},
{
"@type": "Question",
"name": "Quel traitement est recommandé en cas d'intoxication aux tétrahydroisoquinoléines ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le traitement comprend l'administration de charbon actif et des soins de soutien."
}
},
{
"@type": "Question",
"name": "Y a-t-il des antidotes pour les tétrahydroisoquinoléines ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Actuellement, il n'existe pas d'antidote spécifique pour les tétrahydroisoquinoléines."
}
},
{
"@type": "Question",
"name": "Comment gérer les effets secondaires des tétrahydroisoquinoléines ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "La gestion des effets secondaires implique des soins symptomatiques et un suivi médical."
}
},
{
"@type": "Question",
"name": "Les tétrahydroisoquinoléines nécessitent-elles une hospitalisation ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une hospitalisation peut être nécessaire en cas de symptômes graves ou d'intoxication sévère."
}
},
{
"@type": "Question",
"name": "Quels médicaments peuvent interagir avec les tétrahydroisoquinoléines ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des interactions peuvent survenir avec des antidépresseurs et des sédatifs."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir après une intoxication ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications neurologiques et cardiovasculaires peuvent survenir après une intoxication."
}
},
{
"@type": "Question",
"name": "Les tétrahydroisoquinoléines peuvent-elles causer des dommages permanents ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une exposition prolongée peut entraîner des dommages neurologiques permanents."
}
},
{
"@type": "Question",
"name": "Y a-t-il des risques de dépendance aux tétrahydroisoquinoléines ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines personnes peuvent développer une dépendance, surtout avec une utilisation prolongée."
}
},
{
"@type": "Question",
"name": "Comment les tétrahydroisoquinoléines affectent-elles la santé mentale ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles peuvent exacerber des troubles mentaux existants et provoquer des crises d'anxiété."
}
},
{
"@type": "Question",
"name": "Les tétrahydroisoquinoléines peuvent-elles interagir avec d'autres médicaments ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elles peuvent interagir avec des médicaments psychotropes et des analgésiques."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque d'intoxication aux tétrahydroisoquinoléines ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent l'exposition professionnelle et la consommation récréative."
}
},
{
"@type": "Question",
"name": "Les antécédents médicaux influencent-ils le risque ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents de troubles mentaux ou d'addiction augmentent le risque."
}
},
{
"@type": "Question",
"name": "Les personnes âgées sont-elles plus à risque ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les personnes âgées peuvent être plus sensibles aux effets des tétrahydroisoquinoléines."
}
},
{
"@type": "Question",
"name": "Le mode de vie influence-t-il le risque d'intoxication ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un mode de vie à risque, comme la consommation de drogues, augmente le risque."
}
},
{
"@type": "Question",
"name": "Les interactions médicamenteuses augmentent-elles le risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines interactions peuvent accroître la toxicité des tétrahydroisoquinoléines."
}
}
]
}
]
}
Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale
Validation scientifique effectuée le 12/03/2026
Contenu vérifié selon les dernières recommandations médicales
4 publications dans cette catégorie
Affiliations :
Department of Chemistry University College London 20 Gordon Street London WC1H 0AJ UK.
Publications dans "Tétrahydroisoquinoléines" :
4 publications dans cette catégorie
Affiliations :
Department of Chemistry University College London 20 Gordon Street London WC1H 0AJ UK.
Publications dans "Tétrahydroisoquinoléines" :
4 publications dans cette catégorie
Affiliations :
Department of Biochemical Engineering University College London Gower Street, Bernard Katz Building London WC1E 6BT UK.
Publications dans "Tétrahydroisoquinoléines" :
3 publications dans cette catégorie
Affiliations :
Department of Biochemical Engineering University College London Gower Street, Bernard Katz Building London WC1E 6BT UK.
School of Biosciences University of Kent K ent CT2 7NJ UK.
Publications dans "Tétrahydroisoquinoléines" :
3 publications dans cette catégorie
Affiliations :
Department of Chemistry, Christopher Ingold Building, University College London, London, WC1H 0AJ, UK.
Publications dans "Tétrahydroisoquinoléines" :
3 publications dans cette catégorie
Affiliations :
Department of Chemistry, Christopher Ingold Building, University College London, London, WC1H 0AJ, UK.
Publications dans "Tétrahydroisoquinoléines" :
3 publications dans cette catégorie
Affiliations :
Fraunhofer Institute for Interfacial Engineering and Biotechnology IGB, Schulgasse 11a, 94315, Straubing, Germany.
Publications dans "Tétrahydroisoquinoléines" :
3 publications dans cette catégorie
Affiliations :
Institute of Pharmaceutical Sciences, University of Freiburg, Albertstrasse 25, 79104, Freiburg, Germany.
Publications dans "Tétrahydroisoquinoléines" :
3 publications dans cette catégorie
Affiliations :
The Warren and Katharine Schlinger Laboratory for Chemistry and Chemical Engineering, Division of Chemistry and Chemical Engineering, California Institute of Technology, Pasadena, California 91125, United States.
Publications dans "Tétrahydroisoquinoléines" :
2 publications dans cette catégorie
Affiliations :
Department of Medicinal Chemistry, College of Pharmacy , University of Michigan , Ann Arbor , Michigan 48109 , United States.
Publications dans "Tétrahydroisoquinoléines" :
2 publications dans cette catégorie
Affiliations :
Department of Pharmacology, Medical School , University of Michigan , Ann Arbor , Michigan 48109 , United States.
Edward F. Domino Research Center, Medical School , University of Michigan , Ann Arbor , Michigan 48109 , United States.
Publications dans "Tétrahydroisoquinoléines" :
2 publications dans cette catégorie
Affiliations :
Department of Pharmacology, Medical School , University of Michigan , Ann Arbor , Michigan 48109 , United States.
Publications dans "Tétrahydroisoquinoléines" :
2 publications dans cette catégorie
Affiliations :
Department of Pharmacology, Medical School , University of Michigan , Ann Arbor , Michigan 48109 , United States.
Edward F. Domino Research Center, Medical School , University of Michigan , Ann Arbor , Michigan 48109 , United States.
Publications dans "Tétrahydroisoquinoléines" :
2 publications dans cette catégorie
Affiliations :
Department of Medicinal Chemistry, College of Pharmacy , University of Michigan , Ann Arbor , Michigan 48109 , United States.
Edward F. Domino Research Center, Medical School , University of Michigan , Ann Arbor , Michigan 48109 , United States.
Publications dans "Tétrahydroisoquinoléines" :
2 publications dans cette catégorie
Affiliations :
Department Key Laboratory for Green Chemical Process of Ministry of Education, Wuhan Institute of Technology, Wuhan, 430205, China.
Publications dans "Tétrahydroisoquinoléines" :
2 publications dans cette catégorie
Affiliations :
Department Key Laboratory for Green Chemical Process of Ministry of Education, Wuhan Institute of Technology, Wuhan, 430205, China.
Publications dans "Tétrahydroisoquinoléines" :
2 publications dans cette catégorie
Affiliations :
Department Key Laboratory for Green Chemical Process of Ministry of Education, Wuhan Institute of Technology, Wuhan, 430205, China.
Publications dans "Tétrahydroisoquinoléines" :
2 publications dans cette catégorie
Affiliations :
Laboratory of Medicinal Chemistry, Chulabhorn Research Institute, and Program in Chemical Biology, Chulabhorn Graduate Institute, Bangkok 10210, Thailand; Center of Excellence on Environmental Health and Toxicology, Commission on Higher, Education (CHE), Ministry of Education, Thailand.
Publications dans "Tétrahydroisoquinoléines" :
2 publications dans cette catégorie
Affiliations :
The Warren and Katharine Schlinger Laboratory for Chemistry and Chemical Engineering, Division of Chemistry and Chemical Engineering, California Institute of Technology, Pasadena, California 91125, United States.
Publications dans "Tétrahydroisoquinoléines" :
2 publications dans cette catégorie
Affiliations :
State Key Laboratory of Bio-organic and Natural Products Chemistry, Center for Excellence in Molecular Synthesis, Shanghai Institute of Organic Chemistry, University of Chinese Academy of Sciences, Chinese Academy of Sciences, 345 Lingling Road, Shanghai, 200032, China.
Publications dans "Tétrahydroisoquinoléines" :
Retinal pathological neovascularization involves endothelial cells, pericytes, photoreceptor cells, ganglion cells, and glial cells, whose roles remain unclear. Using the Scissor algorithm, we found t...
This study aimed to report eleven cases of non-neovascular pachychoroid disease with hyperreflective material (HRM) that occurred in Japanese patients....
A retrospective review of data from eleven patients who had non-neovascular retinal pigment epithelium (RPE) protrusion with HRM in the neurosensory retina between March 2017 and June 2022 was conduct...
All cases had RPE protrusion and HRM with dilated choroidal veins, which were characteristic of pachychoroid disease. However, none of the cases had macular neovascularization (MNV). In 9 eyes (81.8%)...
There are some cases of non-neovascular pachychoroid disorder with HRM, which might be a new entity of pachychoroid spectrum disease or an early stage of PPE or FCE. These cases should not be misdiagn...
Diabetic retinopathy (DR) is a common complication of diabetes, and recent findings have shown that long noncoding RNAs (lncRNAs) may be involved in its pathogenesis. Through bioinformatics analysis, ...
We used RT‒PCR to assess the expression levels of lncRNA ATP2B2-IT2 and vascular endothelial growth factor (VEGF) in HRMECs under normal glucose (5.5 mmol/L) and high glucose (30 mmol/L) conditions. H...
RT‒PCR revealed that the expression levels of the lncRNA ATP2B2-IT2 and VEGF were greater in the HG group than in the NG group (P < 0.05). After silencing of the lncRNA ATP2B2-IT2, the expression of V...
LncRNA ATP2B2-IT2 may promote the proliferation, migration and neovascularization of HRMECs under high-glucose conditions....
To report the cumulative incidence and risk factors of second eye involvement after diagnosis of myopic macular neovascularization (MNV) in the first eye....
Retrospective analysis of longitudinal data from a tertiary hospital in the Netherlands....
Patients with high myopia (spherical equivalent [SE] ≤ - 6 diopters [D]), of European ethnicity, who were diagnosed with active MNV lesion in 1 eye between 2005 and 2018. Fellow eyes were free of MNV ...
Incidence rate and 2-, 5-, and 10-year cumulative incidences were calculated; hazard ratios (HRs) of second eye involvement were analyzed for potential risk factors using Cox proportional hazard model...
Incidence of second eye involvement after onset of myopic MNV in the first eye....
We included 88 patients over a period of 13 years with a mean age of 58 ± 15 years, mean axial length of 30 ± 1.7 mm and SE -14 ± 4 D at baseline. Twenty-four fellow eyes (27%) developed a myopic MNV ...
Our study of high myopes of European descent shows very similar incidence rates for second eye myopic MNV compared with Asian studies. Our findings substantiate the importance for clinicians to monito...
The authors have no proprietary or commercial interest in any materials discussed in this article....
Angiogenesis is the biological process in which existing blood vessels generate new ones and it is essential for body growth and development, wound healing, and granulation tissue formation. Vascular ...
Microvascular imaging is required to understand tumor angiogenesis development; however, an appropriate whole-body imaging method has not yet been established. Here, we successfully developed a supram...
Unstable atherosclerotic carotid plaques with intraplaque neovascularization (IPN) carry a substantial risk for ischemic stroke. Conventional ultrasound methods fall short in detecting IPN, where supe...
A cohort of twenty-nine patients with ≥50% atherosclerotic carotid stenosis underwent conventional carotid ultrasound, SMI, and blood tests, including measurement of FGF-23 in plasma. Nineteen patient...
Our major findings were: i) Higher FGF-23 levels were strongly correlated with increased SMI-assessed IPN. ii) Neo-vessel count recorded by quantitative SMI was positively correlated to increased FGF-...
This pilot study suggest the potential of FGF-23 as a valuable marker for neovascularization and atherosclerotic carotid plaque instability as a risk factor for ischemic stroke. Further research invol...
Extensive neovascularization, closely linked to massive intraoperative blood loss, is a pathological hallmark of placenta accreta spectrum (PAS) cases. This study aims to explore proteins related to n...
The isobaric tags for relative and absolute quantitation technique were used to identify and quantify the differentially expressed proteins in placentas from PAS and healthy pregnant women. Immunofluo...
Periostin (POSTN) exhibited higher expression in PAS placentas than in normal placentas. Moreover, the overexpression of POSTN in endothelial cells promoted cell proliferation, mobility, and endotheli...
Elevated POSTN expression in PAS is associated with increased angiogenesis, indicating its potential as a molecular marker for significant intraoperative blood loss....
The formation of vascular structures is fundamental for in vitro tissue engineering. Vascularization can enable the nutrient supply within larger structures and increase transplantation efficiency. We...
The purpose of this study was to investigate the effect of diabetic retinopathy (DR) on longitudinal morphological changes in AMD-associated type 1 macular neovascularization using optical coherence t...